MAIA Biotechnology Announces Annual Meeting Date and Virtual Format
Ticker: MAIA · Form: DEF 14A · Filed: Apr 16, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | DEF 14A |
| Filed Date | Apr 16, 2024 |
| Risk Level | |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Virtual Meeting, Board of Directors, Independent Auditor
TL;DR
<b>MAIA Biotechnology will hold its virtual Annual Shareholder Meeting on May 24, 2024, to elect directors and ratify auditors.</b>
AI Summary
MAIA Biotechnology, Inc. (MAIA) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. Annual Shareholder Meeting scheduled for May 24, 2024, at 10:00 a.m. CT. Meeting will be conducted in a virtual format at www.virtualshareholdermeeting.com/MAIA2024. Shareholders cannot attend the meeting in-person. Agenda includes election of directors (Vlad Vitoc, Ramiro Guerrero, Cristian Luput) and ratification of Grant Thornton LLP as independent auditor. Record date for voting eligibility is March 28, 2024.
Why It Matters
For investors and stakeholders tracking MAIA Biotechnology, Inc., this filing contains several important signals. The shift to a virtual-only format may impact shareholder participation and engagement. Key decisions regarding board composition and auditor appointment will be made, influencing company governance and financial oversight.
Risk Assessment
Risk Level: — MAIA Biotechnology, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A proxy statement with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Shareholders should review the proxy materials to understand the director nominees and auditor ratification before the May 24th meeting.
Key Numbers
- May 24, 2024 — Annual Meeting Date (Date of the Annual Meeting of Shareholders)
- 10:00 a.m. CT — Annual Meeting Time (Time of the Annual Meeting of Shareholders)
- March 28, 2024 — Record Date (Shareholders of record on this date are entitled to vote)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- Vlad Vitoc (person) — Director nominee
- Ramiro Guerrero (person) — Director nominee
- Cristian Luput (person) — Director nominee
- Grant Thornton LLP (company) — Independent registered public accounting firm
FAQ
When did MAIA Biotechnology, Inc. file this DEF 14A?
MAIA Biotechnology, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 16, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by MAIA Biotechnology, Inc. (MAIA).
Where can I read the original DEF 14A filing from MAIA Biotechnology, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by MAIA Biotechnology, Inc..
What are the key takeaways from MAIA Biotechnology, Inc.'s DEF 14A?
MAIA Biotechnology, Inc. filed this DEF 14A on April 16, 2024. Key takeaways: Annual Shareholder Meeting scheduled for May 24, 2024, at 10:00 a.m. CT.. Meeting will be conducted in a virtual format at www.virtualshareholdermeeting.com/MAIA2024.. Shareholders cannot attend the meeting in-person..
Is MAIA Biotechnology, Inc. a risky investment based on this filing?
Based on this DEF 14A, MAIA Biotechnology, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A proxy statement with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading MAIA Biotechnology, Inc.'s DEF 14A?
Shareholders should review the proxy materials to understand the director nominees and auditor ratification before the May 24th meeting. The overall sentiment from this filing is neutral.
How does MAIA Biotechnology, Inc. compare to its industry peers?
MAIA Biotechnology operates in the pharmaceutical preparations industry, focusing on drug development and related services.
Are there regulatory concerns for MAIA Biotechnology, Inc.?
The filing is a standard proxy statement (DEF 14A) required by the SEC for public companies holding annual shareholder meetings.
Industry Context
MAIA Biotechnology operates in the pharmaceutical preparations industry, focusing on drug development and related services.
Regulatory Implications
The filing is a standard proxy statement (DEF 14A) required by the SEC for public companies holding annual shareholder meetings.
What Investors Should Do
- Review the list of director nominees and their qualifications.
- Understand the role and appointment of Grant Thornton LLP as the independent auditor.
- Follow instructions to access and participate in the virtual annual meeting.
Key Dates
- 2024-05-24: Annual Meeting of Shareholders — Shareholders will vote on director elections and auditor ratification.
- 2024-03-28: Record Date — Determines eligibility to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine disclosure for an upcoming annual meeting and does not represent a change from previous filings of this type.
Filing Stats: 4,450 words · 18 min read · ~15 pages · Grade level 11.5 · Accepted 2024-04-16 16:01:51
Filing Documents
- ny20019222x1_def14a.htm (DEF 14A) — 579KB
- ny20019222x1_pc01.jpg (GRAPHIC) — 518KB
- ny20019222x1_pc02.jpg (GRAPHIC) — 533KB
- 0001140361-24-020060.txt ( ) — 2027KB
From the Filing
DEF 14A 1 ny20019222x1_def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A (Rule 14a-101)   INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material Pursuant to Rule 14a-ll (c) or Rule 14a-12 MAIA Biotechnology, Inc. (Name of Registrant as Specified In Its Charter) Payment of Filing Fee (Check all boxes that apply): ☒ ​ ​ No fee required.   ☐ ​ ​ Fee paid previously with preliminary materials.   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 NOTICE OF INTENT TO CONVENE IN VIRTUAL MEETING FORMAT THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD MAY 24, 2024 To the Shareholders of MAIA Biotechnology, Inc.: Notice is hereby given that the annual meeting (“Annual Meeting”) of Shareholders of MAIA Biotechnology, Inc. (the “Company”) will be held on May 24, 2024, at 10:00 a.m., Central Time (CT). The board of directors has determined to convene and conduct the Annual Meeting on May 24, 2024 at 10:00 a.m. Central Time, in a virtual meeting format at www.virtualshareholdermeeting.com/MAIA2024. Shareholders will NOT be able to attend the Annual Meeting in-person. The accompanying Proxy Statement includes instruction on how to access the virtual Annual Meeting and how to listen, vote, and submit questions from home or any remote location with Internet connectivity. At the Annual Meeting, we will consider and vote upon the following items: 1 To elect Vlad Vitoc, Ramiro Guerrero, and Cristian Luput to our board of directors as Class II directors of the Company; 2 To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2024; and 3. To consider such other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Only shareholders of record as of the close of business on March 28, 2024, the record date, are entitled to receive notice of, and to vote on-line at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. You are cordially invited to participate in the Annual Meeting. Whether or not you expect to participate in the Annual Meeting, please complete, date, sign and return the enclosed proxy or submit your proxy through the internet or by telephone as promptly as possible in order to ensure your representation at the Annual Meeting. If you have requested physical materials to be mailed to you, then a return envelope (which is postage prepaid if mailed in the United States) is enclosed for your convenience if you choose to submit your proxy by mail. Even if you have voted by proxy, you may still vote online if you attend the virtual Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record. Only shareholders of record at the close of business on the record date may vote at the Annual Meeting or any adjournment or postponement thereof. This notice is being sent to all shareholders of record entitled to vote at the Annual Meeting on or about April 16, 2024.   ​ ​ BY ORDER OF THE BOARD,   ​ ​ /s/ Vlad Vitoc   ​ ​ Vlad Vitoc   ​ ​ Chairman of the Board Chicago, Illinois ​ ​   April 16, 2024 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Shareholders to be held on May 24, 2024 This Proxy Statement and our Annual Report on Form 10-K for the Year Ended December 31, 2023 are available at https://ir.maiabiotech.com/sec-filings/all-sec-filings. MAIA BIOTECHNOLOGY, INC.   444 West Lake Street, Suite 1700 Chicago, Illinois 60606   PROXY STATEMENT This proxy statement sets forth information relating to the solicitation of proxies by the board of directors of MAIA Biotechnology, Inc. (the “Company”) in connection with the Company’s 2024 Annual Meeting of shareholders or any adjournment or postponement o